-
Abstract Number: 2281
Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
-
Abstract Number: 2282
Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response
-
Abstract Number: 2283
Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry
-
Abstract Number: 2284
Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice
-
Abstract Number: 2285
Safety and Tolerability of a Combination of Curcumin, Omega-3 and Vitamin-D: Results from the PASCOD Study, an RA Prevention Protocol
-
Abstract Number: 2286
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
-
Abstract Number: 2287
Hydroxychloroquine and the Risk of Lymphoma Progression in Sjogren’s Disease: A Retrospective Case Control Study
-
Abstract Number: 2288
Interferon Gamma Signaling Is Associated with Development of Extraglandular Manifestations in Sjögren’s Disease
-
Abstract Number: 2289
Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study
-
Abstract Number: 2290
Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology
-
Abstract Number: 2291
The Relationship of the ESSDAI to Health-Related Quality of Life in People Living with Sjogren’s Disease
-
Abstract Number: 2292
Fibroblasts with High Expression of CD74 Promote Lymphocytes Infiltration in Salivary Gland in Sjӧgren’s Disease
-
Abstract Number: 2293
Altered Expression of the MicroRNA Biogenesis Machinery Components Correlates with Inflammatory Parameters in Salivary Glands of Patient with Sjögren’s Disease
-
Abstract Number: 2294
Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study
-
Abstract Number: 2295
Association of Early Markers in Patients with Sjögren’s Syndrome in a Diverse Academic Cohort
- « Previous Page
- 1
- …
- 152
- 153
- 154
- 155
- 156
- …
- 181
- Next Page »